Manchester Incubator Building
48 Grafton Street
Greater Manchester
M13 9XX
+44 (0) 161 276 7123
+44 (0) 161 276 7240
Davin Blain
Renovo is the world leader in scar prevention and reduction research, developing pharmaceutical products to prevent and reduce scarring in the skin, blood vessels, eyes, nerves, internal organs, tendons and ligaments. Our pipeline is extensive and includes four products in phase II clinical development, a further four advanced pre-clinical candidates and nine other pre-clinical candidates. There is an estimated multi-billion dollar global market for anti-scarring drugs, and Renovo aims to be first to market with a scar prevention pharmaceutical drug in the US and Europe to capitalise on this huge, unmet market need.
| Description | Report Date | Published |
|---|---|---|
| Annual Report 2009 | 30-09-2009 | 15-12-2009 |
| Annual Report 2008 | 30-09-2008 | 11-12-2008 |
| Annual Report 2007 | 30-09-2007 | 13-12-2007 |
| Annual Report 2006 | 30-09-2006 | 14-12-2006 |
| Description | Report Date | Published |
|---|---|---|
| Interim Report 2009 | 31-03-2009 | 19-05-2009 |
| Interim Report 2008 | 31-03-2008 | 29-05-2008 |
| Interim Report 2007 | 31-03-2007 | 20-06-2007 |
| Description |
|---|
| Investor Relations |
| Preliminary Results |
| Site Map |
| Events Calendar |
| Home |
| Results Index |
| Contacts |
| Type | Dividend | Payment Date |
|---|